Thursday, 03 January, 2019

Global Ostomy Care Market

Global Ostomy Care market was valued at $2.7bn in 2015 and is forecast to grow at a modest 4.5% CAGR between 2015 and 2024 to reach sales of $4.2bn in 2024. Accessories are an important part of the product offering within ostomy care and include personal hygiene products for skin protection, odour removal and elastic tapes and belts for improved security.

Europe dominates the ostomy care market and accounted for 55% of the market in 2015, although there is a growing contribution from emerging…

Category: Biopharmaceuticals
No Comment

Thursday, 03 January, 2019

Global Pulmonary Arterial Hypertension Market

Global Pulmonary Arterial Hypertension (PAH) market was valued at $5.0bn in 2015 and is forecast to grow at a modest 6.0% CAGR between 2015 and 2024, to result in 2024 global sales of $9.0bn.

PAH is broadly split into two classes, primary or secondary. Primary pulmonary hypertension (PPH) refers to pulmonary hypertension occurring without an identifiable cause. Secondary pulmonary arterial hypertension (PAH) occurs in association with some other identifiable medical condition.

Key players…

Category: Biopharmaceuticals
No Comment

Thursday, 03 January, 2019

Global Rheumatology Treatment Market

Global rheumatology market was valued at $31bn in 2015 and is forecast to grow at a modest 4.0% CAGR between 2015 and 2024 to reach 2024 global sales of $46bn.

Rheumatology encompasses numerous musculoskeletal and autoimmune diseases that cause systemic manifestations including joint pain, inflammation and destruction. Worldwide, over 470 million people suffer from rheumatologic diseases. Rheumatology represents a significant disease burden with annual costs associated with rheumatologic…

Category: Biopharmaceuticals
20 Comments

Thursday, 03 January, 2019

Global Cancer Treatment Market

The global cancer treatment market was valued at $95bn in 2016 and is forecast to grow at a strong 7.2.% CAGR between 2018 and 2023, resulting in 2023 global sales of $155bn driven by targeted therapies & strong market uptake of a range of Immuno-Oncology (IO) treatments.

Worldwide, more than 14 million new cases of cancer are diagnosed each year and this number is expected to increase to 24 million by 2035. Global spending on cancer treatment increased to $100 billion from $75 five years…

Category: Biopharmaceuticals
4 Comments

Thursday, 03 January, 2019

Global Hemophilia Treatment Market

Global hemophilia treatment market was valued at $10.2bn in 2015 and is forecast to grow at a modest 5.4% CAGR between 2015 and 2024, culminating in 2024 global sales of $17.2bn.

Hemophilia is a rare inherited bleeding disorder whereby blood does not clot normally. Predominantly, hemophilia is classified as hemophilia A and hemophilia B. Hemophilia A occurs when the body is unable to produce adequate amounts of factor VIII (FVIII), while patients with hemophilia B are unable to produce…

Category: Biopharmaceuticals
1 Comments

Thursday, 03 January, 2019

Global Hepatitis B Virus (HBV) Treatment Market

Global HBV market was valued at $eri2.8bn in 2015 and is forecast to grow at a modest CAGR of 1.8% between 2015 and 2024, reaching 2024 sales of $3.3bn.

Globally, 350 million people are living with Chronic Hepatitis B (CHB) infection currently. CHB affects up to 2.2 million people in the U.S. Because of the high incidence and risk of liver injury, CHB is a major global health and economic burden. Every year, close to a million people die due to CHB infection related complications including…

Category: Biopharmaceuticals
229 Comments

Thursday, 03 January, 2019

Global Hepatitis C (HCV) Treatment Market

HCV market was valued at $12.5bn in 2015 and is forecast to contract 4.1% CAGR between 2015 and 2024, reaching 2024 global sales of $8.2bn. The volume of HCV patients who will be treated over the next several years is expected to decline resulting in market contraction.

There are 5 key discovery programs that could disrupt the HCV landscape in the foreseeable future.  These include 1) Gilead's triplet at EASL, 2) Merck's nuke study, 3) Achillion's doublet nuke regimen, 4) Regulus' novel…

Category: Biopharmaceuticals
54 Comments

Thursday, 03 January, 2019

Global Lung Cancer Treatment Market

Lung cancer is the 2nd most common cancer in both men (after prostate) and women (after breast cancer). It is one of the most aggressive cancers and the leading cause of cancer death in the world, more than colon, breast, and prostate cancers combined. According to estimates by the American Cancer Society, approximately 223,000 new cases will be diagnosed and approximately 156,000 people will die of this disease in 2017.

The global lung cancer drugs market was valued at $3.1bn in 2017 and is…

Category: Lung Cancers
No Comment

Thursday, 03 January, 2019

U.S. Human Microbiome Market

The U.S. Human Microbiome Market is expected to exhibit a CAGR of 14.3% during the forecast period (2019–2023), advanced technologies, diagnostic and therapeutic applications, rising prevalence and incidence in different types of cancers expect to induce the market growth.

The human microbiome plays a wide range of roles, including influencing the development and function of our immune systems, providing essential nutrients, regulating metabolism, and protecting from severe infections also…

Category: Biopharmaceuticals
No Comment